Search

Your search keyword '"Cai, Qing-Qing"' showing total 262 results
Start Over Author "Cai, Qing-Qing"
262 results on '"Cai, Qing-Qing"'

6. Diagnostic performance and prognostic value of circulating tumor DNA methylation marker in extranodal natural killer/T cell lymphoma

Author

Tian, Xiao-Peng, Zhang, Yu-Chen, Lin, Ning-Jing, Wang, Liang, Li, Zhi-Hua, Guo, Han-Guo, Ma, Shu-Yun, An, Ming-Jie, Yang, Jing, Hong, Yu-Heng, Wang, Xian-Huo, Zhou, Hui, Li, Ya-Jun, Rao, Hui-Lan, Li, Mei, Hu, Shao-Xuan, Lin, Tong-Yu, Li, Zhi-Ming, Huang, He, Liang, Yang, Xia, Zhong-Jun, Lv, Yue, Liu, Yu-Ying, Duan, Zhao-Hui, Chen, Qing-Yu, Wang, Jin-Ni, Cai, Jun, Xie, Ying, Ong, Choon-Kiat, Liu, Fang, Liu, Yan-yan, Yan, Zheng, Huang, Liang, Tao, Rong, Li, Wen-Yu, Huang, Hui-Qiang, and Cai, Qing-Qing

Published
2023
Full Text
View/download PDF

7. Follicle stimulating hormone controls granulosa cell glutamine synthesis to regulate ovulation.

Author

Zhang, Kai-Hui, Zhang, Fei-Fei, Zhang, Zhi-Ling, Fang, Ke-Fei, Sun, Wen-Xing, Kong, Na, Wu, Min, Liu, Hai-Ou, Liu, Yan, Li, Zhi, Cai, Qing-Qing, Wang, Yang, Wei, Quan-Wei, Lin, Peng-Cheng, Lin, Yan, Xu, Wei, Xu, Cong-Jian, Yuan, Yi-Yuan, and Zhao, Shi-Min

Abstract

Polycystic ovary syndrome (PCOS) is the leading cause of anovulatory infertility. Inadequate understanding of the ovulation drivers hinders PCOS intervention. Herein, we report that follicle stimulating hormone (FSH) controls follicular fluid (FF) glutamine levels to determine ovulation. Murine ovulation starts from FF-exposing granulosa cell (GC) apoptosis. FF glutamine, which decreases in pre-ovulation porcine FF, elevates in PCOS patients FF. High-glutamine chow to elevate FF glutamine inhibits mouse GC apoptosis and induces hormonal, metabolic, and morphologic PCOS traits. Mechanistically, follicle-development-driving FSH promotes GC glutamine synthesis to elevate FF glutamine, which maintain follicle wall integrity by inhibiting GC apoptosis through inactivating ASK1-JNK apoptotic pathway. FSH and glutamine inhibit the rapture of cultured murine follicles. Glutamine removal or ASK1-JNK pathway activation with metformin or AT-101 reversed PCOS traits in PCOS models that are induced with either glutamine or EsR1 -KO. These suggest that glutamine, FSH, and ASK1-JNK pathway are targetable to alleviate PCOS. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma

Author

Lim, Jing Quan, Huang, Dachuan, Tang, Tiffany, Tan, Daryl, Laurensia, Yurike, Peng, Rou-Jun, Wong, Esther Kam Yin, Cheah, Daryl Ming Zhe, Chia, Burton Kuan Hui, Iqbal, Jabed, Grigoropoulos, Nicholas Francis, Nairismägi, Maarja-Liisa, Ng, Cedric Chuan Young, Rajasegaran, Vikneswari, Hong, Huangming, Kim, Seok Jin, Cho, Junhun, Tse, Eric, Mow, Benjamin, Cai, Qi-Chun, Poon, Li-Mei, Cai, Qing-qing, Tan, Jing, Chan, Jason Yongsheng, Lim, Johnathan Xiande, Goh, Yeow Tee, Phipps, Colin, Rötzschke, Olaf, Cheng, Chee Leong, Ha, Jeslin Chian Hung, Khoo, Lay Poh, Loh, Yvonne Su Ming, Au-Yeung, Rex, Chan, Thomas Sau-Yan, Kwong, Yok-Lam, Hwang, William, Kim, Won Seog, Bei, Jin-Xin, Lin, Tongyu, Ong, Choon Kiat, and Lim, Soon Thye

Published
2020
Full Text
View/download PDF

9. Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations

Author

Au, Wing-Yan, Chiu, Brian, Fan, Lei, Li, Zheng, LAM, Tai Hing, Liang, Raymond, Yeh, Su-Peng, Xu, Jun, Ip, Dennis Kai Ming, Li, Gandi, Xu, Gang, Wang, Xiaodong, Bai, Ou, Cai, Qing-Qing, Xia, Yi, Chen, Jie-Rong, Luo, Chun-Ling, Xiong, Xiang-Yu, Zeng, Yanni, Wei, Pan-Pan, Liu, Chu-Jun, Liu, Yu-Xiang, Cao, Yu-Lu, He, Shuai, Liu, Yang, Ha, Jeslin Chian Hung, Khoo, Lay Poh, Kee, Rebecca Xiangpin, Tan, Jing, Liu, Yanhui, Zhang, Fen, Feng, Yanfen, Rao, Huilan, Chng, Wee Joo, Chan, Jason Yong Sheng, Somasundaram, Nagavalli D/O, Tao, Miriam, Ras, Mohamad Farid Bin Harunal, Yeoh, Kheng-Wei, Goh, Yeow Tee, Ong, Shin Yeu, Grigoropoulos, Nicholas Francis, Wong, Esther Kam Yin, Pang, Jane Wan Lu, Lim, Jing Quan, Chia, Burton Kuan Hui, Kim, Seok Jin, Yoon, Sang Eun, Choi, Seungkyu, Kuo, Ching-Yuan, Chen, Tsai-Yun, Su, Yu-Chieh, Huang, Wen-Tsung, Lee, Ming-Yang, Yao, Wenxiu, Ngan, Kai-Cheong, Liu, Herman, Lee, Harold, Yip, Sze-Fai, Liu, Jie, Li, Jianyong, Rabkin, Charles S., Berndt, Sonja, Bassig, Bryan, Hu, Wei, Zhao, Mingfeng, Li, Yuming, Zhai, Qiongli, Shao, Zonghong, Qiu, Lugui, Wang, Jianxiang, Xu, Fu-Ping, Chen, Ling, Hou, Yu, Xu, Shuangnian, Huang, Zhen, Xie, Mingling, Li, Ming, Zhong, Shilong, Zhang, Yan, Gu, Dongqing, Wang, Xin, Foo, Jia Nee, Li, Zhiqiang, Dai, Juncheng, Sun, Liangdan, Wang, Zhenzhen, Liu, Hong, Zhou, Hui, Sun, Yonghu, Koh, Woon-Puay, Heng, Chew-Kiat, Hong, Chew Soo, Ahn, Jeeyun, Park, Kyu Hyung, Tin, Aung, Gu, Jieruo, Xia, Xiaojun, Li, Bo, Yu, Xueqing, Lin, Guo-Wang, Xu, Caigang, Chen, Kexin, Huang, Hui-Qiang, Chen, Jieping, Song, Bao, Chan, John K C, Li, Wenyu, Liu, Weiping, Shih, Lee-Yung, Chuang, Wen-Yu, Kim, Won Seog, Tan, Wen, Peng, Rou-Jun, Laurensia, Yurike, Cheah, Daryl Ming Zhe, Huang, DaChuan, Cheng, Chee Leong, Su, Yi-Jiun, Tan, Soo-Yong, Ng, Siok-Bian, Tang, Tiffany Pooi Ling, Han, Kyudong, Wang, Vivien Ya-Fan, Jia, Wei-Hua, Pei, Zhong, Li, Ya-Jun, Gao, Song, Shi, Yongyong, Hu, Zhibin, Zhang, Furen, Zhang, Ben, Zeng, Yi-Xin, Shen, Hongbing, He, Lin, Ong, Choon Kiat, Lim, Soon Thye, Chanock, Stephen, Kwong, Yok-Lam, Lin, Dongxin, Rothman, Nathaniel, Khor, Chiea Chuen, Lan, Qing, and Bei, Jin-Xin

Published
2020
Full Text
View/download PDF

10. A gene-expression-based signature predicts survival in adults with T-cell lymphoblastic lymphoma: a multicenter study

Author

Tian, Xiao-Peng, Xie, Dan, Huang, Wei-Juan, Ma, Shu-Yun, Wang, Liang, Liu, Yan-Hui, Zhang, Xi, Huang, Hui-Qiang, Lin, Tong-Yu, Rao, Hui-Lan, Li, Mei, Liu, Fang, Zhang, Fen, Zhong, Li-Ye, Liang, Li, Lan, Xiao-Liang, Li, Juan, Liao, Bing, Li, Zhi-Hua, Tang, Qiong-Lan, Liang, Qiong, Shao, Chun-Kui, Zhai, Qiong-Li, Cheng, Run-Fen, Sun, Qi, Ru, Kun, Gu, Xia, Lin, Xi-Na, Yi, Kun, Shuang, Yue-Rong, Chen, Xiao-Dong, Dong, Wei, Sang, Wei, Sun, Cai, Liu, Hui, Zhu, Zhi-Gang, Rao, Jun, Guo, Qiao-Nan, Zhou, Ying, Meng, Xiang-Ling, Zhu, Yong, Hu, Chang-Lu, Jiang, Yi-Rong, Zhang, Ying, Gao, Hong-Yi, He, Wen-Jun, Xia, Zhong-Jun, Pan, Xue-Yi, Lan, Hai, Li, Guo-Wei, Liu, Lu, Bao, Hui-Zheng, Song, Li-Yan, Kang, Tie-Bang, and Cai, Qing-Qing

Published
2020
Full Text
View/download PDF

12. Prognostic and predictive value of a microRNA signature in adults with T-cell lymphoblastic lymphoma

Author

Tian, Xiao-Peng, Huang, Wei-Juan, Huang, Hui-Qiang, Liu, Yan-Hui, Wang, Liang, Zhang, Xi, Lin, Tong-Yu, Rao, Hui-Lan, Li, Mei, Liu, Fang, Zhang, Fen, Zhong, Li-Ye, Liang, Li, Lan, Xiao-Liang, Li, Juan, Liao, Bing, Li, Zhi-Hua, Tang, Qiong-Lan, Liang, Qiong, Shao, Chun-Kui, Zhai, Qiong-Li, Cheng, Run-Fen, Sun, Qi, Ru, Kun, Gu, Xia, Lin, Xi-Na, Yi, Kun, Shuang, Yue-Rong, Chen, Xiao-Dong, Dong, Wei, Sang, Wei, Sun, Cai, Liu, Hui, Zhu, Zhi-Gang, Rao, Jun, Guo, Qiao-Nan, Zhou, Ying, Meng, Xiang-Ling, Zhu, Yong, Hu, Chang-Lu, Jiang, Yi-Rong, Zhang, Ying, Gao, Hong-Yi, He, Wen-Jun, Xia, Zhong-Jun, Wu, Cheng-Lei, Zhang, Mei-Yin, Wang, Hui-Yun, Xie, Dan, and Cai, Qing-Qing

Published
2019
Full Text
View/download PDF

14. Real‐world treatment and outcome patterns of patients with mantle cell lymphoma in China: A large, multicenter retrospective analysis

Author

Yang, Ping, primary, Cai, Qing‐qing, additional, Zhang, Wei, additional, Liu, Shuo‐zi, additional, Liu, Hui, additional, Sun, Xiu‐hua, additional, Dong, Yu‐jun, additional, Xiao, Xiu‐bin, additional, Wang, Jing‐wen, additional, Li, Zhen‐ling, additional, Huang, Wen‐rong, additional, Li, Li‐hong, additional, Bao, Hui‐zheng, additional, Yang, Wei, additional, Wang, Ya‐lan, additional, Wang, Shu‐ye, additional, He, Juan, additional, Li, Xiao‐ling, additional, Liu, Ai‐chun, additional, and Jing, Hong‐mei, additional

Published
2023
Full Text
View/download PDF

19. Supplementary Figure S19 from A CpG Methylation Classifier to Predict Relapse in Adults with T-Cell Lymphoblastic Lymphoma

Author

Tian, Xiao-Peng, primary, Su, Ning, primary, Wang, Liang, primary, Huang, Wei-Juan, primary, Liu, Yan-Hui, primary, Zhang, Xi, primary, Huang, Hui-Qiang, primary, Lin, Tong-Yu, primary, Ma, Shu-Yun, primary, Rao, Hui-Lan, primary, Li, Mei, primary, Liu, Fang, primary, Zhang, Fen, primary, Zhong, Li-Ye, primary, Liang, Li, primary, Lan, Xiao-Liang, primary, Li, Juan, primary, Liao, Bing, primary, Li, Zhi-Hua, primary, Tang, Qiong-Lan, primary, Liang, Qiong, primary, Shao, Chun-Kui, primary, Zhai, Qiong-Li, primary, Cheng, Run-Fen, primary, Sun, Qi, primary, Ru, Kun, primary, Gu, Xia, primary, Lin, Xi-Na, primary, Yi, Kun, primary, Shuang, Yue-Rong, primary, Chen, Xiao-Dong, primary, Dong, Wei, primary, Sun, Cai, primary, Sang, Wei, primary, Liu, Hui, primary, Zhu, Zhi-Gang, primary, Rao, Jun, primary, Guo, Qiao-Nan, primary, Zhou, Ying, primary, Meng, Xiang-Ling, primary, Zhu, Yong, primary, Hu, Chang-Lu, primary, Jiang, Yi-Rong, primary, Zhang, Ying, primary, Gao, Hong-Yi, primary, He, Wen-Jun, primary, Xia, Zhong-Jun, primary, Pan, Xue-Yi, primary, Hai, Lan, primary, Li, Guo-Wei, primary, Song, Li-Yan, primary, Kang, Tie-Bang, primary, Xie, Dan, primary, and Cai, Qing-Qing, primary

Published
2023
Full Text
View/download PDF

20. Supplementary Table S3 from A CpG Methylation Classifier to Predict Relapse in Adults with T-Cell Lymphoblastic Lymphoma

Author

Tian, Xiao-Peng, primary, Su, Ning, primary, Wang, Liang, primary, Huang, Wei-Juan, primary, Liu, Yan-Hui, primary, Zhang, Xi, primary, Huang, Hui-Qiang, primary, Lin, Tong-Yu, primary, Ma, Shu-Yun, primary, Rao, Hui-Lan, primary, Li, Mei, primary, Liu, Fang, primary, Zhang, Fen, primary, Zhong, Li-Ye, primary, Liang, Li, primary, Lan, Xiao-Liang, primary, Li, Juan, primary, Liao, Bing, primary, Li, Zhi-Hua, primary, Tang, Qiong-Lan, primary, Liang, Qiong, primary, Shao, Chun-Kui, primary, Zhai, Qiong-Li, primary, Cheng, Run-Fen, primary, Sun, Qi, primary, Ru, Kun, primary, Gu, Xia, primary, Lin, Xi-Na, primary, Yi, Kun, primary, Shuang, Yue-Rong, primary, Chen, Xiao-Dong, primary, Dong, Wei, primary, Sun, Cai, primary, Sang, Wei, primary, Liu, Hui, primary, Zhu, Zhi-Gang, primary, Rao, Jun, primary, Guo, Qiao-Nan, primary, Zhou, Ying, primary, Meng, Xiang-Ling, primary, Zhu, Yong, primary, Hu, Chang-Lu, primary, Jiang, Yi-Rong, primary, Zhang, Ying, primary, Gao, Hong-Yi, primary, He, Wen-Jun, primary, Xia, Zhong-Jun, primary, Pan, Xue-Yi, primary, Hai, Lan, primary, Li, Guo-Wei, primary, Song, Li-Yan, primary, Kang, Tie-Bang, primary, Xie, Dan, primary, and Cai, Qing-Qing, primary

Published
2023
Full Text
View/download PDF

22. Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study

Author

Li, Zheng, Xia, Yi, Feng, Li-Na, Chen, Jie-Rong, Li, Hong-Min, Cui, Jing, Cai, Qing-Qing, Sim, Kar Seng, Nairismägi, Maarja-Liisa, Laurensia, Yurike, Meah, Wee Yang, Liu, Wen-Sheng, Guo, Yun-Miao, Chen, Li-Zhen, Feng, Qi-Sheng, Pang, Chi Pui, Chen, Li Jia, Chew, Soo Hong, Ebstein, Richard P, Foo, Jia Nee, Liu, Jianjun, Ha, Jeslin, Khoo, Lay Poh, Chin, Suk Teng, Zeng, Yi-Xin, Aung, Tin, Chowbay, Balram, Diong, Colin Phipps, Zhang, Fen, Liu, Yan-Hui, Tang, Tiffany, Tao, Miriam, Quek, Richard, Mohamad, Farid, Tan, Soo Yong, Teh, Bin Tean, Ng, Siok Bian, Chng, Wee Joo, Ong, Choon Kiat, Okada, Yukinori, Raychaudhuri, Soumya, Lim, Soon Thye, Tan, Wen, Peng, Rou-Jun, Khor, Chiea Chuen, and Bei, Jin-Xin

Published
2016
Full Text
View/download PDF

23. Correction to: Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma

Author

Lim, Jing Quan, Huang, Dachuan, Tang, Tiffany, Tan, Daryl, Laurensia, Yurike, Peng, Rou-Jun, Wong, Esther Kam Yin, Cheah, Daryl Ming Zhe, Chia, Burton Kuan Hui, Iqbal, Jabed, Grigoropoulos, Nicholas Francis, Nairismägi, Maarja-Liisa, Ng, Cedric Chuan Young, Rajasegaran, Vikneswari, Hong, Huangming, Kim, Seok Jin, Cho, Junhun, Tse, Eric, Mow, Benjamin, Cai, Qi-Chun, Poon, Li-Mei, Cai, Qing-qing, Tan, Jing, Chan, Jason Yongsheng, Lim, Johnathan Xiande, Goh, Yeow Tee, Phipps, Colin, Rötzschke, Olaf, Cheng, Chee Leong, Ha, Jeslin Chian Hung, Khoo, Lay Poh, Loh, Yvonne Su Ming, Au-Yeung, Rex, Chan, Thomas Sau-Yan, Kwong, Yok-Lam, Hwang, William, Kim, Won Seog, Bei, Jin-Xin, Lin, Tongyu, Ong, Choon Kiat, and Lim, Soon Thye

Published
2021
Full Text
View/download PDF

26. Analysis of albumin as a prognostic factor in HHV-8/HIV-negative Castleman disease from a multicenter study

Author

Yu, Tiantian, primary, Cai, Qing-Qing, additional, Zhai, Qiong-Li, additional, Li, Ling, additional, Fang, Xiaosheng, additional, Li, Jianyong, additional, Sun, Ruifang, additional, Yang, Hanjin, additional, Wang, Zhaoming, additional, Qian, Wenbian, additional, Xu-Monette, Zijun Y., additional, Young, Ken H., additional, and Yu, Li, additional

Published
2022
Full Text
View/download PDF

28. A genomic‐augmented multivariate prognostic model for the survival of natural‐killer/T‐cell lymphoma patients from an international cohort

Author

Lim, Jing Quan, primary, Huang, Dachuan, additional, Chan, Jason Yongsheng, additional, Laurensia, Yurike, additional, Wong, Esther Kam Yin, additional, Cheah, Daryl Ming Zhe, additional, Chia, Burton Kuan Hui, additional, Chuang, Wen‐Yu, additional, Kuo, Ming‐Chung, additional, Su, Yi‐Jiun, additional, Cai, Qing‐qing, additional, Feng, Yanfen, additional, Rao, Huilan, additional, Feng, Li‐Na, additional, Wei, Pan‐Pan, additional, Chen, Jie‐Rong, additional, Han, Bo‐Wei, additional, Lin, Guo‐Wang, additional, Cai, Jun, additional, Fang, Yu, additional, Tan, Jing, additional, Hong, Huangming, additional, Liu, Yanhui, additional, Zhang, Fen, additional, Li, Wenyu, additional, Poon, Michelle L. M., additional, Ng, Siok‐Bian, additional, Jeyasekharan, Anand, additional, Ha, Jeslin Chian Hung, additional, Khoo, Lay Poh, additional, Chin, Suk Teng, additional, Pang, Wan Lu, additional, Kee, Rebecca, additional, Cheng, Chee Leong, additional, Grigoropoulos, Nicholas Francis, additional, Tang, Tiffany, additional, Tao, Miriam, additional, Farid, Mohamad, additional, Puan, Kia Joo, additional, Xiong, Jie, additional, Zhao, Wei‐Li, additional, Khor, Chiea Chuen, additional, Hwang, William, additional, Kim, Won Seog, additional, Campo, Elias, additional, Tan, Patrick, additional, Teh, Bin Tean, additional, Chng, Wee‐Joo, additional, Rötzschke, Olaf, additional, Tousseyn, Thomas, additional, Huang, Hui‐Qiang, additional, Rozen, Steve, additional, Lim, Soon Thye, additional, Shih, Lee‐Yung, additional, Bei, Jin‐Xin, additional, and Ong, Choon Kiat, additional

Published
2022
Full Text
View/download PDF

30. Real-world treatment and outcome patterns of patients with mantle cell lymphoma in China: a large, multicenter retrospective analysis

Author

Yang, Ping, primary, Cai, Qing-qing, additional, Zhang, Wei, additional, Liu, Shuo-zi, additional, Liu, Hui, additional, Sun, Xiu-hua, additional, Dong, Yu-jun, additional, Xiao, Xiu-bin, additional, Wang, Jing-wen, additional, Li, Zhen-ling, additional, Huang, Wen-rong, additional, Li, Li-hong, additional, Bao, Hui-zheng, additional, Yang, Wei, additional, Wang, Ya-lan, additional, Wang, Shu-ye, additional, He, Juan, additional, Li, Xiao-ling, additional, Liu, Ai-chun, additional, and Jing, Hongmei, additional

Published
2022
Full Text
View/download PDF

33. Combination of PD‐1 inhibitor with GVD (gemcitabine, vinorelbine, liposomal doxorubicin) versus GVD regimen as second‐line therapy for relapsed/refractory classical Hodgkin lymphoma

Author

Zhang, Yu‐Chen, primary, Wang, Jin‐Ni, additional, Ma, Shu‐Yun, additional, Cai, Jun, additional, Su, Ning, additional, Huang, Hui‐Qiang, additional, Li, Zhi‐Ming, additional, Xia, Zhong‐Jun, additional, Huang, He, additional, Liu, Pan‐Pan, additional, Xia, Yi, additional, and Cai, Qing-Qing, additional

Published
2021
Full Text
View/download PDF

34. The beneficial effect of Escalated‐R‐CHOP‐21 for the treatment of diffuse large B‐cell lymphoma in elderly male patients: A propensity‐matched cohort study

Author

He, Hai‐Xia, primary, Gao, Yan, additional, Bai, Bing, additional, Wang, Xiao‐Xiao, additional, Li, Ji‐Bin, additional, Huang, Cheng, additional, Mao, Jia‐Ying, additional, Ping, Li‐Qin, additional, Rong, Qi‐Xiang, additional, He, Yan‐Xia, additional, Huang, He, additional, Cai, Qing‐Qing, additional, Li, Zhi‐Ming, additional, Jiang, Wen‐Qi, additional, and Huang, Hui‐Qiang, additional

Published
2021
Full Text
View/download PDF

40. A composite single-nucleotide polymorphism prediction signature for extranodal natural killer/T-cell lymphoma

Author

Tian, Xiao-Peng, primary, Ma, Shu-Yun, additional, Young, Ken H., additional, Ong, Choon Kiat, additional, Liu, Yan-Hui, additional, Li, Zhi-Hua, additional, Zhai, Qiong-Li, additional, Huang, Hui-Qiang, additional, Lin, Tong-Yu, additional, Li, Zhi-Ming, additional, Xia, Zhong-Jun, additional, Zhong, Li-Ye, additional, Rao, Hui-Lan, additional, Li, Mei, additional, Cai, Jun, additional, Zhang, Yu-Chen, additional, Zhang, Fen, additional, Su, Ning, additional, Li, Peng-Fei, additional, Zhu, Feng, additional, Xu-Monette, Zijun Y., additional, Wong, Esther Kam Yin, additional, Ha, Jeslin Chian Hung, additional, Khoo, Lay Poh, additional, Ai, Le, additional, Cheng, Run-Fen, additional, Lim, Jing Quan, additional, de Mel, Sanjay, additional, Ng, Siok-Bian, additional, Lim, Soon Thye, additional, and Cai, Qing-Qing, additional

Published
2021
Full Text
View/download PDF

42. Metagenomic next-generation sequencing (mNGS) confirmed a critical case of severe fever with thrombocytopenia syndrome virus (SFTSV).

Author

Zhu, Tong, Cai, Qing-Qing, Yu, Jiao, and Liang, Xue-Song

Subjects
*NUCLEOTIDE sequencing, *RIBAVIRIN, *METAGENOMICS, *FEVER, *THROMBOCYTOPENIA, *SYNDROMES, *MANNITOL
Abstract

Keywords: endemic; hemophagocytic lymphohistiocytos; metagenomic next-generation sequencing; misdiagnosis; severe fever with thrombocytopenia syndrome virus EN endemic hemophagocytic lymphohistiocytos metagenomic next-generation sequencing misdiagnosis severe fever with thrombocytopenia syndrome virus e42 e45 4 01/07/22 20220115 NES 220115 To the Editor, Severe fever with thrombocytopenia syndrome (SFTS) is an emerging tick-borne disease caused by SFTS virus (SFTSV) of family I Bunyaviridae i , which is endemic in China, South Korea, and Japan, with high mortality (12-32%) and undiagnostic or misdiagnosis rate [[1]], [[2]], [[3]], [[4]]. Further re-collecting the epidemic history of the patient and found the patient had been staying in Sanjie Town, Anhui Province, an SFTSV endemic area, for 22 days before the fever onset. Fortunately, the patient was admitted to hospital relatively early, and received comprehensive treatment options, including early ribavirin antiviral therapy thanks to timely pathogen diagnose by mNGS. [Extracted from the article]

Published
2022
Full Text
View/download PDF

43. Combination of PD‐1 inhibitor with GVD (gemcitabine, vinorelbine, liposomal doxorubicin) versus GVD regimen as second‐line therapy for relapsed/refractory classical Hodgkin lymphoma.

Author

Zhang, Yu‐Chen, Wang, Jin‐Ni, Ma, Shu‐Yun, Cai, Jun, Su, Ning, Huang, Hui‐Qiang, Li, Zhi‐Ming, Xia, Zhong‐Jun, Huang, He, Liu, Pan‐Pan, Xia, Yi, and Cai, Qing-Qing

Subjects
HODGKIN'S disease, PROGRAMMED cell death 1 receptors, VINORELBINE, POSITRON emission tomography, DOXORUBICIN, ANAPLASTIC lymphoma kinase
Abstract

Summary: Patients with classical Hodgkin lymphoma (cHL) who do not achieve complete remission (CR) after second‐line chemotherapy have poor clinical outcomes. Besides, conventional salvage chemotherapy regimens have an unsatisfactory CR rate. The present retrospective study reports the efficacy and toxicity of the GVD (gemcitabine, vinorelbine, liposomal doxorubicin) regimen with or without programmed cell death 1 (PD‐1) inhibitor for patients with cHL who failed first‐line treatment. A total of 103 patients with cHL (GVD+PD‐1 group, n = 27; GVD group, n = 76) with response assessment based on positron emission tomography were included. The GVD+PD‐1 group tended to have a higher CR rate than GVD group (85·2% vs. 65·8%, P = 0·057) and had a better event‐free survival (EFS) (P = 0·034). Subgroup analysis showed that patients with low‐risk second‐line International Prognostic Score might benefit from the addition of PD‐1 inhibitor (GVD+PD‐1 vs. GVD, 100·0% vs. 64·7%, P = 0·028) and had better EFS than GVD alone (P = 0·016). Further analysis demonstrated that PD‐1 consolidation therapy might provide an EFS benefit (P = 0·007). The toxicity of the GVD+PD‐1 regimen was comparable to the GVD regimen, except for higher rates of hypothyroidism and autoimmune pneumonitis, which were manageable. In conclusion, combining a PD‐1 inhibitor with a GVD regimen could be a potentially effective second‐line therapy for patients with cHL. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

44. Bortezomib in combination with fludarabine plus cyclophosphamide for patients with relapsed or refractory mantle-cell lymphoma: results of the LYM-4003 study.

Author

Wang, Xiao-Xiao, Gao, Yan, Jin, Jie, Cao, Jun-Ning, Feng, Ji-Feng, Wang, Hua-Qing, Zhang, Hui-Lai, Cai, Qing-Qing, Li, Zhi-Ming, Jiang, Wen-Qi, and Huang, Hui-Qiang

Subjects
CYCLOPHOSPHAMIDE, FLUDARABINE, OVERALL survival, SURVIVAL rate, BORTEZOMIB
Abstract

This study aimed to identify the maximum-tolerated dose (MTD) of cyclophosphamide when combined with bortezomib and fludarabine (B-FC) in a phase 1b trial, and to assess the efficacy and safety of this combination in a phase 2 trial in patients with relapsed or refractory MCL (rrMCL). Forty patients were enrolled between April 8, 2011, and October 10, 2015. The MTD of cyclophosphamide was identified to be 250 mg/m2 days 1–2. At a median follow-up of 31.6 months (13.5–47.4), among 32 patients in phase 2, 10 (31%) had a complete response and 13 (41%) had a partial response. The median progression-free survival was 21 months (95% CI 7.3–34.7), and the median overall survival was 32.4 months (95% CI 17.8–47.0). Grade 3–4 hematologic AEs included neutropenia (27%) and thrombocytopenia (39%). The B-FC regimen has satisfactory responses and manageable toxicities in rrMCL patients (ClinicalTrials.gov NCT01322776). [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

45. A CpG Methylation Classifier to Predict Relapse in Adults with T-Cell Lymphoblastic Lymphoma

Author

Tian, Xiao-Peng, primary, Su, Ning, additional, Wang, Liang, additional, Huang, Wei-Juan, additional, Liu, Yan-Hui, additional, Zhang, Xi, additional, Huang, Hui-Qiang, additional, Lin, Tong-Yu, additional, Ma, Shu-Yun, additional, Rao, Hui-Lan, additional, Li, Mei, additional, Liu, Fang, additional, Zhang, Fen, additional, Zhong, Li-Ye, additional, Liang, Li, additional, Lan, Xiao-Liang, additional, Li, Juan, additional, Liao, Bing, additional, Li, Zhi-Hua, additional, Tang, Qiong-Lan, additional, Liang, Qiong, additional, Shao, Chun-Kui, additional, Zhai, Qiong-Li, additional, Cheng, Run-Fen, additional, Sun, Qi, additional, Ru, Kun, additional, Gu, Xia, additional, Lin, Xi-Na, additional, Yi, Kun, additional, Shuang, Yue-Rong, additional, Chen, Xiao-Dong, additional, Dong, Wei, additional, Sun, Cai, additional, Sang, Wei, additional, Liu, Hui, additional, Zhu, Zhi-Gang, additional, Rao, Jun, additional, Guo, Qiao-Nan, additional, Zhou, Ying, additional, Meng, Xiang-Ling, additional, Zhu, Yong, additional, Hu, Chang-Lu, additional, Jiang, Yi-Rong, additional, Zhang, Ying, additional, Gao, Hong-Yi, additional, He, Wen-Jun, additional, Xia, Zhong-Jun, additional, Pan, Xue-Yi, additional, Hai, Lan, additional, Li, Guo-Wei, additional, Song, Li-Yan, additional, Kang, Tie-Bang, additional, Xie, Dan, additional, and Cai, Qing-Qing, additional

Published
2020
Full Text
View/download PDF

46. BRD2 induces drug resistance through activation of the RasGRP1/Ras/ERK signaling pathway in adult T‐cell lymphoblastic lymphoma

Author

Tian, Xiao‐Peng, primary, Cai, Jun, additional, Ma, Shu‐Yun, additional, Fang, Yu, additional, Huang, Hui‐Qiang, additional, Lin, Tong‐Yu, additional, Rao, Hui‐Lan, additional, Li, Mei, additional, Xia, Zhong‐Jun, additional, Kang, Tie‐Bang, additional, Xie, Dan, additional, and Cai, Qing‐Qing, additional

Published
2020
Full Text
View/download PDF

47. Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations

Author

Lin, Guo-Wang, primary, Xu, Caigang, additional, Chen, Kexin, additional, Huang, Hui-Qiang, additional, Chen, Jieping, additional, Song, Bao, additional, Chan, John K C, additional, Li, Wenyu, additional, Liu, Weiping, additional, Shih, Lee-Yung, additional, Chuang, Wen-Yu, additional, Kim, Won Seog, additional, Tan, Wen, additional, Peng, Rou-Jun, additional, Laurensia, Yurike, additional, Cheah, Daryl Ming Zhe, additional, Huang, DaChuan, additional, Cheng, Chee Leong, additional, Su, Yi-Jiun, additional, Tan, Soo-Yong, additional, Ng, Siok-Bian, additional, Tang, Tiffany Pooi Ling, additional, Han, Kyudong, additional, Wang, Vivien Ya-Fan, additional, Jia, Wei-Hua, additional, Pei, Zhong, additional, Li, Ya-Jun, additional, Gao, Song, additional, Shi, Yongyong, additional, Hu, Zhibin, additional, Zhang, Furen, additional, Zhang, Ben, additional, Zeng, Yi-Xin, additional, Shen, Hongbing, additional, He, Lin, additional, Ong, Choon Kiat, additional, Lim, Soon Thye, additional, Chanock, Stephen, additional, Kwong, Yok-Lam, additional, Lin, Dongxin, additional, Rothman, Nathaniel, additional, Khor, Chiea Chuen, additional, Lan, Qing, additional, Bei, Jin-Xin, additional, Au, Wing-Yan, additional, Chiu, Brian, additional, Fan, Lei, additional, Li, Zheng, additional, LAM, Tai Hing, additional, Liang, Raymond, additional, Yeh, Su-Peng, additional, Xu, Jun, additional, Ip, Dennis Kai Ming, additional, Li, Gandi, additional, Xu, Gang, additional, Wang, Xiaodong, additional, Bai, Ou, additional, Cai, Qing-Qing, additional, Xia, Yi, additional, Chen, Jie-Rong, additional, Luo, Chun-Ling, additional, Xiong, Xiang-Yu, additional, Zeng, Yanni, additional, Wei, Pan-Pan, additional, Liu, Chu-Jun, additional, Liu, Yu-Xiang, additional, Cao, Yu-Lu, additional, He, Shuai, additional, Liu, Yang, additional, Ha, Jeslin Chian Hung, additional, Khoo, Lay Poh, additional, Kee, Rebecca Xiangpin, additional, Tan, Jing, additional, Liu, Yanhui, additional, Zhang, Fen, additional, Feng, Yanfen, additional, Rao, Huilan, additional, Chng, Wee Joo, additional, Chan, Jason Yong Sheng, additional, Somasundaram, Nagavalli D/O, additional, Tao, Miriam, additional, Ras, Mohamad Farid Bin Harunal, additional, Yeoh, Kheng-Wei, additional, Goh, Yeow Tee, additional, Ong, Shin Yeu, additional, Grigoropoulos, Nicholas Francis, additional, Wong, Esther Kam Yin, additional, Pang, Jane Wan Lu, additional, Lim, Jing Quan, additional, Chia, Burton Kuan Hui, additional, Kim, Seok Jin, additional, Yoon, Sang Eun, additional, Choi, Seungkyu, additional, Kuo, Ching-Yuan, additional, Chen, Tsai-Yun, additional, Su, Yu-Chieh, additional, Huang, Wen-Tsung, additional, Lee, Ming-Yang, additional, Yao, Wenxiu, additional, Ngan, Kai-Cheong, additional, Liu, Herman, additional, Lee, Harold, additional, Yip, Sze-Fai, additional, Liu, Jie, additional, Li, Jianyong, additional, Rabkin, Charles S., additional, Berndt, Sonja, additional, Bassig, Bryan, additional, Hu, Wei, additional, Zhao, Mingfeng, additional, Li, Yuming, additional, Zhai, Qiongli, additional, Shao, Zonghong, additional, Qiu, Lugui, additional, Wang, Jianxiang, additional, Xu, Fu-Ping, additional, Chen, Ling, additional, Hou, Yu, additional, Xu, Shuangnian, additional, Huang, Zhen, additional, Xie, Mingling, additional, Li, Ming, additional, Zhong, Shilong, additional, Zhang, Yan, additional, Gu, Dongqing, additional, Wang, Xin, additional, Foo, Jia Nee, additional, Li, Zhiqiang, additional, Dai, Juncheng, additional, Sun, Liangdan, additional, Wang, Zhenzhen, additional, Liu, Hong, additional, Zhou, Hui, additional, Sun, Yonghu, additional, Koh, Woon-Puay, additional, Heng, Chew-Kiat, additional, Hong, Chew Soo, additional, Ahn, Jeeyun, additional, Park, Kyu Hyung, additional, Tin, Aung, additional, Gu, Jieruo, additional, Xia, Xiaojun, additional, Li, Bo, additional, and Yu, Xueqing, additional

Published
2020
Full Text
View/download PDF

49. Recurrent PD-L1 Structural Rearrangements in Natural Killer/T Cell Lymphoma Patients with Complete Response to PD-1 Blockade Therapy

Author

Lim, Jing-Quan, Tang, Tiffany, Cai, Qing-qing, Tan, Daryl, Nairismägi, Maarja-Liisa, Laurensia, Yurike, Chia, Burton Kuan Hui, Peng, Rou-Jun, Iqbal, Jabed, Huang, Da Chuan, Song, Tammy, Pang, Wan Lu, Cheah, Daryl Ming Zhe, Young Ng, Cedric Chuan, Rajasegaran, Vikneswari, Hong, Huangming, Tse, Eric, Mow, Benjamin, Cai, Qi Chun, Poon, Li-Mei, Tan, Jing, Grigoropoulos, Nicholas Francis, Goh, Yeow Tee, Phipps, Colin, Rötzschke, Olaf, Cheng, Chee Leong, Lee, Yuh Shan, Loh, Yvonne, Tao, Miriam, Farid, Mohamad, Au-Yeung, Rex, Chan, Thomas Sau-Yan, Ng, Siok-Bian, Kwong, Yok-Lam, Hwang, William, Chng, Wee-Joo, Tousseyn, Thomas, Tan, Patrick, Teh, Bin Tean, Khor, Chiea Chuen, Rozen, Steve, Bei, Jin-Xin, Lin, Tongyu, Lim, Soon Thye, Ong, Choon Kiat, and ICGC Blood Cancer T-cell and NK-cell lymphoma group

Subjects
Oncology, medicine.medical_specialty, business.industry, ICGC Blood Cancer T-cell and NK-cell lymphoma group, Pembrolizumab, medicine.disease, Natural killer T cell, Blockade, Lymphoma, Refractory, Internal medicine, Cohort, medicine, Immunohistochemistry, business, Progressive disease
Abstract

This study aims to identify recurrent genetic alterations in relapsed or refractory (RR) natural-killer/T-cell lymphoma (NKTL) patients who have achieved complete response (CR) with programmed cell death 1 (PD-1) blockade therapy. Seven of the eleven patients treated with pembrolizumab achieved CR while the remaining four had progressive disease (PD). Using whole genome sequencing (WGS), we found recurrent clonal structural rearrangements (SR) of the PD-L1 gene in four of the seven (57%) CR patients’ pretreated tumors. These PD-L1 SRs consist of inter-chromosomal translocations, tandem duplication and micro-inversion that disrupted the suppressive function of PD-L1 3’UTR. Interestingly, recurrent JAK3-activating (p.A573V) mutations were also validated in two CR patients’ tumors that did not harbor the PD-L1 SR. Importantly, these mutations were absent in the four PD cases. With immunohistochemistry (IHC), PD-L1 positivity could not discriminate patients who archived CR (range: 6%-100%) from patients who had PD (range: 35%-90%). PD-1 blockade with pembrolizumab is a potent strategy for RR NKTL patients and genomic screening could potentially accompany PD-L1 IHC positivity to better select patients for anti-PD-1 therapy.

Published
2018

50. MOESM2 of IL-2RÎą up-regulation is mediated by latent membrane protein 1 and promotes lymphomagenesis and chemotherapy resistance in natural killer/T-cell lymphoma

Author

Wang, Liang, Bi, Xi-Wen, Zhu, Yu-Jia, He, Ying-Zhi, Lai, Qiu-Yu, Xia, Zhong-Jun, and Cai, Qing-Qing

Abstract

Additional file 2: Figure S2. Positron emission tomography-computed tomography of a 42-year-old man with refractory NKTCL before and after treatment with anti-IL-2RÎą antibody (basiliximab) and pegaspargase. Before treatment, diffuse infiltration of lymphoma with high metabolic activity was observed (right panel). After two cycles of treatment, partial remission was observed (left panel).

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results